Global Preclinical Cro Market Size & Outlook, 2023-2030
Global preclinical cro market, 2018-2030 (US$M)
Related Markets
Global preclinical cro market highlights
- The global preclinical cro market generated a revenue of USD 5,715.0 million in 2023 and is expected to reach USD 9,675.8 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 7.8% by 2030.
- In terms of segment, toxicology testing accounted for a revenue of USD 1,450.6 million in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Kuwait is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 5,715.0 million |
| Market revenue in 2030 | USD 9,675.8 million |
| Growth rate | 7.8% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
Other key industry trends
- In terms of revenue, the North America accounted for 47.2% of the global preclinical cro market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Kuwait is the fastest growing regional market and is projected to reach USD 6.0 million by 2030.
Toxicology testing was the largest segment with a revenue share of 25.38% in 2023. Horizon Databook has segmented the Global preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
The geographical distribution of R&D activities is slowly shifting from developed nations to emerging countries. Rising R&D expenditure coupled with an increase in failure rates of R&D activities has caused biopharmaceutical companies to prefer regions such as Central and Eastern Europe, Asia Pacific, and Latin America & Middle East for ensuring cost saving and quick patient recruitment.
Outsourcing of preclinical trials to regions such as Asia Pacific also provides greater economic benefits to biopharmaceutical companies. Governments of countries such as Singapore and China are allocating funds to promote biomedical research in this region.
Besides, as a large number of clinical trials are being conducted in countries of Asia Pacific and Latin America regions, preclinical trials are also expected to follow the same trend. This would allow preclinical testing to be conducted in close proximity to central development centers conducting clinical trials.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global preclinical cro market size, by regions, 2018-2030 (US$M)
Top 10 countries: Preclinical cro market size, 2023 (US$M)
Global preclinical cro market share, by service, 2023 & 2030 (%, US$M)
Preclinical cro market: Opportunity assessment by country
Global preclinical cro market, by region, 2023 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
